(Q47321232)

14 January 2018

title

No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation (English)

1 reference

14 January 2018

1 reference

7

J Hebebrand

1 reference

14 January 2018

6

H Remschmidt

1 reference

14 January 2018

F M Theisen

1

1 reference

14 January 2018

M Haberhausen

2

1 reference

14 January 2018

M A Firnges

3

1 reference

14 January 2018

P Gregory

4

1 reference

14 January 2018

J H Reinders

5

1 reference

14 January 2018

J Antel

8

1 reference

14 January 2018

publication date

19 September 2006

1 reference

14 January 2018

The Pharmacogenomics Journal

published in

1 reference

14 January 2018

volume

7

1 reference

14 January 2018

issue

4

1 reference

14 January 2018

page(s)

275-281

1 reference

14 January 2018

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500418

exact match

0 references

cites work

Body weight gain induced by antipsychotic drugs: mechanisms and management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Clozapine-induced weight gain: prevalence and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Clozapine and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Clozapine's effects on body weight and resting metabolic rate: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Pharmacogenetics of antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

A prospective study of serum ghrelin levels in patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

No evidence for a direct effect of clozapine on fat-cell formation and production of leptin and other fat-cell-derived factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Effects of clozapine on plasma cytokine and soluble cytokine receptor levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

KO's and organisation of peptidergic feeding behavior mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Central effects of calcitonin receptor-stimulating peptide-1 on energy homeostasis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Cannabinoids and the regulation of ingestive behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Bradykinin B2 receptor gene C-58T polymorphism and insulin resistance. A study on obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

The bradykinin BK2 receptor mediates angiotensin II receptor type 2 stimulated rat duodenal mucosal alkaline secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Fundamentals of neurogastroenterology: basic science

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Muscarinic mechanisms of antipsychotic atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

5-ht6 receptors as emerging targets for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Atypical neuroleptics in child and adolescent psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Genetic variants of the serotonin system and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Serum leptin levels increase rapidly after initiation of clozapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

7 January 2021

Pharmacogenetics of antipsychotic-induced weight gain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

7 January 2021

Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3 receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

7 January 2021

How to appease the appetite of psychotropic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500418

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500418

1 reference

14 January 2018

Dimensions Publication ID

1044423559

0 references

1 reference

14 January 2018